Literature DB >> 31628637

Bone Marrow Failure in Children: Approach to Diagnosis and Treatment.

Hannah Fassel1, Sujit Sheth2.   

Abstract

Bone marrow failure has many different etiologies, including genetic defects which manifest with specific syndromes, as well as acquired conditions as a result of insults to the bone marrow leading to aplasia. The clinical picture is varied and clues for the underlying cause may or may not be evident at the time of presentation, frequently leading to a complex workup with a battery of tests often done to rule out genetic defects. The treatment approach for bone marrow failure is very dependent on the underlying cause, which makes it all the more critical to have an accurate diagnosis. First line management essentially consists of either hematopoietic stem cell transplant or immunosuppressive therapy. In this review authors will provide a broad look at the causes of bone marrow failure, the stepwise diagnostic algorithm and the approach to decision making for treatment. Fine details of each cause, and of each treatment modality are beyond the scope of this review which aims to provide an overview.

Entities:  

Keywords:  Hematopoietic stem cell transplantation; Immunosuppression; Inherited bone marrow failure syndromes; Secondary aplastic anemia

Mesh:

Substances:

Year:  2019        PMID: 31628637     DOI: 10.1007/s12098-019-03066-4

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  38 in total

1.  Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.

Authors:  Phillip Scheinberg; Olga Nunez; Barbara Weinstein; Priscila Scheinberg; Colin O Wu; Neal S Young
Journal:  Blood       Date:  2011-11-08       Impact factor: 22.113

2.  Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.

Authors:  Ronan Desmond; Danielle M Townsley; Bogdan Dumitriu; Matthew J Olnes; Phillip Scheinberg; Margaret Bevans; Ankur R Parikh; Kinneret Broder; Katherine R Calvo; Colin O Wu; Neal S Young; Cynthia E Dunbar
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

3.  Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.

Authors:  Mary Eapen; Jennifer Le Rademacher; Joseph H Antin; Richard E Champlin; Jeanette Carreras; Joseph Fay; Jakob R Passweg; Jakub Tolar; Mary M Horowitz; Judith C W Marsh; H Joachim Deeg
Journal:  Blood       Date:  2011-06-15       Impact factor: 22.113

4.  Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Authors:  E Di Bona; F Rodeghiero; B Bruno; A Gabbas; P Foa; A Locasciulli; C Rosanelli; L Camba; P Saracco; A Lippi; A P Iori; F Porta; G De Rossi; B Comotti; P Iacopino; C Dufour; A Bacigalupo; V De Rossi
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

Review 5.  How I manage patients with Fanconi anaemia.

Authors:  Carlo Dufour
Journal:  Br J Haematol       Date:  2017-05-05       Impact factor: 6.998

6.  Eltrombopag and improved hematopoiesis in refractory aplastic anemia.

Authors:  Matthew J Olnes; Phillip Scheinberg; Katherine R Calvo; Ronan Desmond; Yong Tang; Bogdan Dumitriu; Ankur R Parikh; Susan Soto; Angelique Biancotto; Xingmin Feng; Jay Lozier; Colin O Wu; Neal S Young; Cynthia E Dunbar
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

7.  Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party.

Authors:  A Tichelli; G Socié; M Henry-Amar; J Marsh; J Passweg; H Schrezenmeier; S McCann; J Hows; P Ljungman; P Marin; A Raghavachar; A Locasciulli; A Gratwohl; A Bacigalupo
Journal:  Ann Intern Med       Date:  1999-02-02       Impact factor: 25.391

8.  Treatment of the bone marrow failure in Fanconi anemia patients with danazol.

Authors:  Kathrin Scheckenbach; Mary Morgan; Judith Filger-Brillinger; Matthias Sandmann; Bruce Strimling; Wolfram Scheurlen; Detlev Schindler; Ulrich Göbel; Helmut Hanenberg
Journal:  Blood Cells Mol Dis       Date:  2011-12-16       Impact factor: 3.039

9.  Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia.

Authors:  R Storb; R Etzioni; C Anasetti; F R Appelbaum; C D Buckner; W Bensinger; E Bryant; R Clift; H J Deeg; K Doney
Journal:  Blood       Date:  1994-08-01       Impact factor: 22.113

Review 10.  Treatment of aplastic anaemia in elderly patients aged >60 years.

Authors:  A Tichelli; J C W Marsh
Journal:  Bone Marrow Transplant       Date:  2012-11-26       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.